p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent

doi:10.1016/0014-2999(92)90282-9

European Journal of Pharmacology

Volume 229, Issue 1, 8 December 1992, Pages 31-38

https://doi.org/10.1016/0014-2999(92)90282-9 Get rights and content

Abstract

p-Methylthioamphetamine (MTA), was compared to p-chloroamphetamine (PCA) in a number of pharmacological assays. MTA was about 2-fold more potent than PCA at inhibiting synaptosomal uptake of [³H]5-hydroxytryptamine ([³H]5-HT), and about 7-fold and 10-fold less potent than PCA at inhibiting synaptosomal uptake of [³H]dopamine and [³H]norepinephrine, respectively. In drug discrimination assays, MTA was nearly equipotent to PCA in animals trained to discriminate saline from 3,4-methylenedioxymethamphetamine (MDMA), or two related analogues S-(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (S-MBDB) or 5-methoxy-6-methyl-2-aminoindan (MMAI). MTA caused dose-dependent increases of tritium efflux from superfused rat frontal cortex slices preloaded with [³H]5-HT, comparable to that induced by an equal molar concentration of PCA. The potential neurotoxicity of MTA was examined by measuring monoamine and metabolite levels at one week following an acute dose. A 10 mg/kg dose of PCA caused a 70–90% decrease of cortical, hippocampal and striatal 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels, while twice the molar dose of MTA (21.3 mg/kg) had no effect. Thus, MTA is a potent, selective, serotonin releaser, apparently devoid of serotonin neurotoxic effects. This work also supports the idea that catecholamine systems may play a critical role in the neurotoxicity of PCA-like compounds.

References (27)

G. Battaglia et al.
MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
Pharmacol. Biochem. Behav.
(1988)
R.W. Fuller et al.
Long-term effects of 4-chloroamphetamine on brain 5-hydroxyindole metabolism in rats
Neuropharmacology
(1974)
R.W. Fuller et al.
Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: Drug levels in brain and effects on brain serotonin metabolism
Neuropharmacology
(1975)
B.L. Jacobs
An animal behavior model for studying central serotonergic synapses
Life Sci.
(1976)
M.P. Johnson et al.
Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats
Neuropharmacology
(1991)
M.P. Johnson et al.
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue
Pharmacol. Biochem. Behav.
(1991)
M.P. Johnson et al.
Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine
Eur. J. Pharmacol.
(1990)
L.A. Mamounas et al.
Evidence for dual serotonergic projections to neocortex: Axons from the dorsal and median raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA)
Exp. Neurol.
(1988)
J.F. Nash et al.
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues
Eur. J. Pharmacol.
(1991)
M.D. Schechter
Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Pharmacol. Biochem. Behav.
(1988)

C.J. Schmidt et al.

Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue

Eur. J. Pharmacol.

(1986)

T.D. Steele et al.

Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [³H]-monoamines into synaptosomes from different regions of rat brain

Biochem. Pharmacol.

(1987)

M.E. Trulson et al.

Behavioral evidence for rapid release of CNS serotonin by PCA and fenfluramine

Eur. J. Pharmacol.

(1976)

Cited by (62)

Synthetic amphetamine derivatives, benzofurans, and benzodifurans
2021, Novel Psychoactive Substances: Classification, Pharmacology and Toxicology
Synthetic amphetamine derivatives, benzofurans, and benzodifurans are commonly used, ever-growing number of synthetic substances. This chapter reviews the pharmacology, prevalence of use worldwide, as well as evidence of toxicity in animals, and in humans, using case reports of toxicity and deaths when available, with a goal of providing a better understanding of availability, abuse potential, and burden of toxicity from common forms of these substances.
Amphetamine derivatives share a common phenylethylamine chemical skeleton that, with subtle structural modifications, can result in a diverse array of drugs capable of producing varied and discrete clinical effects. The mechanism of action of these agents is stimulated release of biogenic amine neurotransmitters, inhibition of their reuptake, and prevention of their degradation. The paucity of reliable medical information regarding the effects of novel amphetamine derivatives in humans underscores both the need for confirmatory testing in suspected cases and for the clinician to be familiar with structure activity relationships and their expected physiological result. In this chapter we review experimental animal data, self-reported human clinical effects and existing case reports and case series to highlight the clinical effects of amphetamine derivatives. This is a continuingly developing field with new drugs being developed and marketed on an ongoing basis. Drugs are therefore classified by chemical and clinical similarity to assist clinicians with the prediction of potential adverse effects as newer drugs continue to emerge.
Benzofurans are members of the amphetamine and phenylethylamine classes. 6-APB and 5-APB have recently been identified as single furan ring benzofuran compounds used as recreational drugs, producing sympathetic system stimulation and euphoria. There is little information available regarding their toxicity. They are postulated to exert their effects through stimulation of catecholamine receptors and as 5-HT receptor agonists. Benzodifurans (containing 2 heterocyclic rings) including bromo‑dragonFLY and 2-CB-FLY are ring-substituted phenylethylamines with potent 5HT_2A agonist effects and predominant hallucinogenic clinical effects. Bromo-dragonFLY toxicity produces excess sympathomimetic activity and severe vasoconstriction, in some cases resulting in limb amputation. Deaths secondary to bromo‑dragonFLY and mis-identified 2-CB-FLY (containing bromo‑dragonFLY) have occurred in Europe and the USA. Recent surveys of drug users indicate that 6-APB is the most commonly used recreational benzofuran in the UK; although compared to established, classical recreational drugs and other novel psychoactive substances 6-APB and other drugs in this class are rarely used.
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
2014, Neuropharmacology
Citation Excerpt :
The present study showed that all of these para-substituted amphetamines are potent NET and SERT inhibitors with low potency at the DAT, as previously shown for 4-MTA (Huang et al., 1992) and 4-trifluoromethylmethcathinone (Cozzi et al., 2013). These drugs released NE and 5-HT and at high concentrations (>10 μM) also released DA, as previously shown for 4-MTA, PMA, and 4-trifluoromethylmethcathinone in vitro and in vivo (Cozzi et al., 2013; Gobbi et al., 2008; Gough et al., 2002; Huang et al., 1992; Quinn et al., 2006; Sotomayor-Zarate et al., 2012). Importantly, the in vivo hyperthermic properties of the para-substituted amphetamines are stronger than those of MDMA (Daws et al., 2000) and have been associated with serotonergic and adrenergic receptor activation (Carmo et al., 2003).
Psychoactive β-keto amphetamines (cathinones) are sold as “bath salts” or “legal highs” and recreationally abused. We characterized the pharmacology of a new series of cathinones, including methedrone, 4-methylethcathinone (4-MEC), 3-fluoromethcathinone (3-FMC), pentylone, ethcathinone, buphedrone, pentedrone, and N,N-dimethylcathinone. We investigated norepinephrine (NE), dopamine (DA), and serotonin (5-HT) uptake inhibition using human embryonic kidney 293 (HEK 293) cells that express the respective human monoamine transporter, the drug-induced efflux of NE, DA, and 5-HT from monoamine-preloaded cells, and binding affinity to monoamine transporters and receptors. All of the cathinones were potent NE uptake inhibitors but differed in their DA vs. 5-HT transporter inhibition profiles and monoamine release effects. Methedrone was a more potent 5-HT than DA transporter inhibitor and released NE and 5-HT similar to para-methoxymethamphetamine (PMMA), para-methoxyamphetamine (PMA), 4-methylthioamphetamine (4-MTA), and 3,4-methylenedioxymethamphetamine (MDMA). 4-MEC and pentylone equipotently inhibited all of the monoamine transporters and released 5-HT. Ethcathinone and 3-FMC inhibited NE and DA uptake and released NE, and 3-FMC also released DA similar to N-ethylamphetamine and methamphetamine. Pentedrone and N,N-dimethylcathinone were non-releasing NE and DA uptake inhibitors as previously shown for pyrovalerone cathinones. Buphedrone preferentially inhibited NE and DA uptake and also released NE. None of the cathinones bound to rodent trace amine-associated receptor 1, in contrast to the non-β-keto-amphetamines. None of the cathinones exhibited relevant binding to other monoamine receptors. In summary, we found considerable differences in the monoamine transporter interaction profiles among different cathinones and compared with related amphetamines.
Aminoindane Analogues
2013, Novel Psychoactive Substances: Classification, Pharmacology and Toxicology
One of the less well known compound classes of the so-called novel psychoactive substances are represented by analogues and derivatives that are based on the 2-aminoindane nucleus, which due to its structure, is a conformationally rigid analogue of amphetamine. Published animal and in vitro studies of the pharmacological profile of various aminoindanes indicate an involvement of serotonin release and re-uptake. In addition, drug discrimination studies carried out in rats pointed towards some pharmacological properties that are also shared with 3,4-methylenedioxymethamphetamine (MDMA). At first glance, one might be tempted to consider whether such substances would display empathogenic or entactogenic effects similar to MDMA and/or whether drug users might consider these substances as potential MDMA-replacements, particularly those on the lookout for substances that are not under control in most countries. At present there is very limited information about the acute and chronic human toxicity of various aminoindane derivatives, with the extent of current availability and trends in recreational use of this class of drugs being uncertain. However, from a clinical and forensic toxicology perspective, it is important to be able to identify the possible presence of such compounds and their potential metabolites in biological fluids and tissues, also to follow any trend in their use and need for control measures to be introduced. This chapter will provide an account of selected aminoindanes regarding their chemistry, pharmacology and toxicology and concludes that, so far, aminoindanes appear to play a minor role.
Synthetic Amphetamine Derivatives
2013, Novel Psychoactive Substances: Classification, Pharmacology and Toxicology
Amphetamine derivatives share a common phenylethylamine chemical skeleton that, with subtle structural modifications, can result in a diverse array of drugs capable of producing varied and discrete clinical effects. The mechanism of action of these agents is stimulated release of biogenic amine neurotransmitters, inhibition of their reuptake, and prevention of their degradation. The paucity of reliable medical information regarding the effects of novel amphetamine derivatives in humans underscores both the need for confirmatory testing in suspected cases and for the clinician to be familiar with structure activity relationships and their expected physiological result. In this chapter we review experimental animal data, self-reported human clinical effects and existing case reports and case series to highlight the clinical effects of amphetamine derivatives. This is a continuingly developing field with new drugs being developed and marketed on an ongoing basis. Drugs are therefore classified by chemical and clinical similarity to assist clinicians with the prediction of potential adverse effects as newer drugs continue to emerge.
Identification and synthesis of by-products found in 4-methylthioamphetamine (4-MTA) produced by the Leuckart method
2012, Forensic Science International
The synthesis of the designer drug 4-methylthioamphetamine (4-MTA) has been carried out using the well-known Leuckart reaction in four versions. The treatment of 4-methylthiophenylacetone with formamide, mixture of formamide/formic acid, ammonium formate, and mixture of ammonium formate and formic acid followed by acid hydrolysis brought about the formation of 4-MTA contaminated with a number of impurities. The gas chromatography mass–spectrometry (GC–MS) analysis of the reaction mixtures allowed identification of the most prominent impurities, such as diasteromers of N,N-di-[β-(4-methylthiophenyl)isopropyl]amine, N,N-di-[β-(4-methylthiophenyl)isopropyl]methylamine, N,N-di-[β-(4-methylthiophenyl)isopropyl]formamide, the Schiff bases derived from 4-MTA and 4-methylbenzaldehyde (benzaldimine) and 4-methylthiophenylacetone (ketimine) as well as some heterocycles: 4-methyl-5-(4′-methylthiophenyl)pyrimidine, 4-(4′-methylthiobenzyl)pyrimidine, 2,6-dimethyl-3,5-di-(4′-methylthiophenyl)pyridine, 2,4-dimethyl-3,5-di-(4′-methylthiophenyl)pyridine. The correctness of identification was confirmed by independent synthesis of these compounds. Each synthesized reference compound was characterized by means of MS, ¹H and ¹³C NMR, and IR methods. The stereochemistry of (RR/SS) diasteromer of N,N-di-[β-(4-methylthiophenyl)isopropyl]amine was confirmed by a crystallographic method.
Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1- propenes as a new class of anticancer agents
2011, Bioorganic and Medicinal Chemistry
Structural derivatives of 4-MTA, an illegal amphetamine analogue have been previously shown to have anticancer effects in vitro. In this study we report the synthesis of a series of novel 1,3-bis(aryl)-2-nitro-1-propene derivatives related in structure to 4-MTA. A number of these compounds containing a classic nitrostyrene structure are shown to have antiproliferative activities in vitro in a range of malignant cell lines, particularly against Burkitt’s lymphoma derived cell lines, whilst having no effect on ‘normal’ peripheral blood mononuclear cells. Such effects appear to be independent of the serotonin transporter, a high affinity target for amphetamines and independent of protein tyrosine phosphatases and tubulin dynamics both of which have been previously associated with nitrostyrene-induced cell death. We demonstrate that a number of these compounds induce caspase activation, PARP cleavage, chromatin condensation and membrane blebbing in a Burkitt’s lymphoma derived cell line, consistent with these compounds inducing apoptosis in vitro. Although no specific target has yet been identified for the action of these compounds, the cell death elicited is potent, selective and worthy of further investigation.

View all citing articles on Scopus

View full text

p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent

Abstract

Pharmacol. Biochem. Behav.

Neuropharmacology

Neuropharmacology

Life Sci.

Neuropharmacology

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Exp. Neurol.

Eur. J. Pharmacol.

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Biochem. Pharmacol.

Eur. J. Pharmacol.